UK Government Seeks Pharmaceutical Sector's Views on Regulation Enforcement
UK government review will look for unnecessary regulatory burdens and inconsistencies and at guidance clarity.
The UK Department for Business Innovation & Skills is conducting a review of how well national regulators and local authorities enforce rules governing the pharmaceutical sector, and the group is seeking input from pharmaceutical producers, the department announced in a press release. The Focus on Enforcement review will be open for comment on the website and via email until September 2, 2013. The reviewers will also speak with individual businesses, trade bodies, and regulators. A response from regulators will follow the evidence-gathering phase of the review.
Ministers want to hear about any unnecessary burdens that are being placed on businesses and any duplication or inconsistencies between regulatory bodies. The review also seeks to find out whether companies are receiving the clear guidance they need to comply with the law. Firms are also invited to identify areas of good enforcement practice which could be replicated elsewhere.
“The UK pharmaceutical industry is a vital player in an increasingly competitive international market. We must maximize its potential to attract investment, innovate, and create jobs, while maintaining world-class quality and safety standards,” said business minister Michael Fallon in the press release. “I want firms to tell us how we can improve the environment in which they work. We want to make sure regulation is proportionately and intelligently applied to facilitate their contribution to our economy.”
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
